Efficacy News and Research

RSS

BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, is pleased today to announce positive preliminary results in its LIP phase III pivotal study (Lauriad® Immunocompetent Patients Study ). This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg Mucoadhesive Buccal Tablet (MBT) versus matching placebo in patients suffering from recurrent oro-facial herpes.

27 Aug 2009

Consumer Reports covers issues pertaining to the efficacy and safety of prescription and non-prescription drugs

Consumer Reports and ConsumerReportsHealth.org cover issues pertaining to the efficacy and safety of prescription and non-prescription drugs (including natural medicines), mental health, diet and nutrition, food safety, and fitness.

26 Aug 2009

AOFAS announces results of clinical trials with the STAR ankle replacement device

Charles L. Saltzman, MD, newly-elected president of the American Orthopaedic Foot & Ankle Society (AOFAS), presented the results of a groundbreaking study at the recent AOFAS 2009 Annual Summer Meeting in Vancouver, British Columbia, Canada.

26 Aug 2009

Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period

Cardium Therapeutics (NYSE Amex: CXM) today announced that all patients enrolled in the Company's MATRIX clinical study have now completed their initial 12-week evaluation period and that it plans to provide detailed safety and efficacy data in late September 2009.

26 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.

26 Aug 2009

Virginia Tech researchers to help pre-diabetic adults begin resistance training for preventing diabetes

Systematic, progressive resistance training - also called strength training - is a safe and efficient way for middle-aged and older adults to improve their health. A Virginia Tech led research team that includes experts in behavior, exercise, physiology, and medicine is designing a program to help pre-diabetic adults begin and, most important, maintain resistance training in order to prevent diabetes.

26 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

FDA accepts Labopharm's response for its novel trazodone formulation

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has accepted Labopharm's response regarding its novel formulation of the antidepressant trazodone as complete and designated it as a Class 2 resubmission. The FDA has assigned Labopharm a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010.

26 Aug 2009

Glaxosmithkline affirms safety of Alli

GSK stands firmly behind the safety and efficacy of alli. Our primary priority is patient health, and we want people to know that there is no evidence that alli causes liver damage.

26 Aug 2009

FDA approves Supersonic Imagine's Aixplorer ultrasound system

SuperSonic Imagine today announced that it has received 510K Clearance from the FDA for its Aixplorer(TM) ultrasound system and will begin to market and deliver the device in the United States. Aixplorer is the only commercially available system of its kind with MultiWave(TM) Technology, which is based upon interaction between conventional longitudinal waves and shear waves in tissue.

26 Aug 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.

25 Aug 2009

Free webinar for business travel industry on swine flu pandemic

"Business as usual” won’t be this flu season, with the effects of the H1N1 (Swine Flu) pandemic expected to include quarantines, travel restrictions and school and office closings. Businesses that rely on travel need to make preparations now to mitigate the impact.

25 Aug 2009

Cybex International re-brands its research division as Cybex Institute For Exercise Science

Cybex International, Inc., a leading manufacturer of premium exercise equipment for the commercial and consumer markets, announced today the re-branding of its research arm as the Cybex Institute for Exercise Science, with the continued mission of disseminating scientifically accurate information applicable to the disciplines of general fitness, sports performance and clinical medicine.

25 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

UCB and sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved XYZAL(R) (levocetirizine dihydrochloride) for children age six months and older for the relief of symptoms of perennial allergic rhinitis (indoor allergies) and chronic idiopathic urticaria (chronic hives) and for children age two years and older for symptoms of seasonal allergic rhinitis (outdoor allergies).

25 Aug 2009

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.

24 Aug 2009

Retigabine's Phase IIa clinical trial preliminary results announced

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles.

24 Aug 2009

Efficacy News and Research

BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results

Consumer Reports covers issues pertaining to the efficacy and safety of prescription and non-prescription drugs

AOFAS announces results of clinical trials with the STAR ankle replacement device

Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Virginia Tech researchers to help pre-diabetic adults begin resistance training for preventing diabetes

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

FDA accepts Labopharm's response for its novel trazodone formulation

Glaxosmithkline affirms safety of Alli

FDA approves Supersonic Imagine's Aixplorer ultrasound system

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Free webinar for business travel industry on swine flu pandemic

Cybex International re-brands its research division as Cybex Institute For Exercise Science

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

UCB and sanofi-aventis U.S. receive FDA's approval for XYZAL to treat allergies in children

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Retigabine's Phase IIa clinical trial preliminary results announced

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News